<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768855</url>
  </required_header>
  <id_info>
    <org_study_id>17793</org_study_id>
    <secondary_id>J3E-MC-EZDA</secondary_id>
    <nct_id>NCT04768855</nct_id>
  </id_info>
  <brief_title>A Study of LY3540378 in Healthy Participants</brief_title>
  <official_title>A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of the study drug&#xD;
      known as LY3540378 in healthy participants following single and multiple doses (Parts A and&#xD;
      B) and multiple doses in Japanese (Part C) and Chinese (Part D) healthy participants. Blood&#xD;
      tests will be performed to check how much LY3540378 gets into the bloodstream and how long it&#xD;
      takes the body to eliminate it. This is a 4-part study and may last up to 70, 113, 113 and&#xD;
      113 days for each participant in Parts A, B, C, and D respectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 113</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3540378</measure>
    <time_frame>Predose on Day 1 through Day 113</time_frame>
    <description>PK: Cmax of LY3540378</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3540378</measure>
    <time_frame>Predose on Day 1 through Day 113</time_frame>
    <description>PK: AUC of LY3540378</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3540378 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3540378 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of LY3540378 administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3540378 (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of LY3540378 administered SC in Japanese Participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3540378 (Part D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of LY3540378 administered SC in Chinese Participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A, B, C &amp; D)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered either IV or SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3540378</intervention_name>
    <description>Administered IV or SC.</description>
    <arm_group_label>LY3540378 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV or SC.</description>
    <arm_group_label>Placebo (Part A, B, C &amp; D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3540378</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3540378 (Part B)</arm_group_label>
    <arm_group_label>LY3540378 (Part C)</arm_group_label>
    <arm_group_label>LY3540378 (Part D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy males or females, as determined by medical history and physical&#xD;
             examination.&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²)&#xD;
&#xD;
          -  For Part C, participants should be first generation Japanese origin.&#xD;
&#xD;
          -  For Part D, participants should be first generation Chinese origin.&#xD;
&#xD;
          -  Male participants must agree to adhere to contraception restrictions and female&#xD;
             participants not of childbearing potential and may include who are infertile due to&#xD;
             surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), or&#xD;
             congenital anomaly such as müllerian agenesis or postmenopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with troponin I results above the upper reference limit judged to be&#xD;
             clinically significant by the investigator&#xD;
&#xD;
          -  Diagnosed with orthostatic hypotension defined as a decrease in systolic blood&#xD;
             pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg within 3&#xD;
             minutes of standing when compared with blood pressure from the sitting or supine&#xD;
             position.&#xD;
&#xD;
          -  Have a significant history of or current cardiovascular (for example, myocardial&#xD;
             infarction, congestive HF, cerebrovascular accident, venous thromboembolism, etc.),&#xD;
             respiratory, renal, gastrointestinal, endocrine, haematological (including history of&#xD;
             thrombocytopenia), or neurological disorders capable of significantly altering the&#xD;
             absorption, metabolism, or elimination of drugs&#xD;
&#xD;
          -  Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis&#xD;
             biliary and pancreatic disorder&#xD;
&#xD;
          -  Have evidence of significant active neuropsychiatric disease as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Have received chronic (lasting &gt;14 consecutive days) systemic glucocorticoid therapy&#xD;
             in the past year, or have received any glucocorticoid therapy within 1 month before&#xD;
             screening&#xD;
&#xD;
          -  Have an abnormality in the 12-lead ECG&#xD;
&#xD;
          -  Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2 × the&#xD;
             upper limit of normal (ULN) or total bilirubin (TBL) &gt;1.5 × ULN&#xD;
&#xD;
          -  Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or&#xD;
             amylase greater than 1.5 × ULN&#xD;
&#xD;
          -  Have known allergies to LY3540378 or related compounds&#xD;
&#xD;
          -  Have donated blood of &gt;450 mL, or have participated in a clinical study that required&#xD;
             similar blood volume drawn within the past 30 calendar days&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 7 units per week, or are unwilling&#xD;
             to stop alcohol consumption as required during the study (1 unit = 12 oz or 360 mL of&#xD;
             beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)&#xD;
&#xD;
          -  Smoke &gt;10 cigarettes per day or the equivalent, or are unable or unwilling to refrain&#xD;
             from nicotine&#xD;
&#xD;
          -  Allergy to iodine (shellfish allergy)&#xD;
&#xD;
          -  Have a history of sensitivity to lithium carbonate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(714) 774-7777</phone>
    </contact>
    <investigator>
      <last_name>Amina Zakaria Haggag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lilly Centre for Clinical Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>65 6413 9811</phone>
    </contact>
    <investigator>
      <last_name>Ronan Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

